GZ 402668
Alternative Names: GZ402668Latest Information Update: 05 Nov 2023
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Monoclonal antibodies
- Mechanism of Action CD52 antigen modulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis